Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US.

Eberly LA, Yang L, Eneanya ND, Essien U, Julien H, Nathan AS, Khatana SAM, Dayoub EJ, Fanaroff AC, Giri J, Groeneveld PW, Adusumalli S. · 2021

Read Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. by Eberly LA, Yang L, Eneanya ND, Essien U, Julien H, Nathan AS, Khatana SAM, Dayoub EJ, Fanaroff AC, Giri J, Groeneveld PW, Adusumalli S. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8050743.txt.

Introduction

Eberly and co-authors check who actually receives SGLT2 inhibitor drugs among U.S. patients with diabetes. These drugs protect the heart and kidneys beyond lowering blood sugar. Guidelines recommend them for patients at high risk. Yet new therapies often reach some groups faster than others. The cohort study covered 934,737 patients with type 2 diabetes.

In the full cohort, only 8.7% received an SGLT2 inhibitor during the study period. Use climbed from 3.8% in 2015 to 11.9% by the end of 2019. Even patients with heart failure, artery disease, or kidney disease lagged far behind. Adjusted analyses found Black patients less likely to receive the drugs, with an adjusted odds ratio of 0.83 for Black patients. Asian patients also trailed, at 0.94 in the same adjusted models. The authors frame the gap as an equity problem.

Catalog record

CREATOREberly LA, Yang L, Eneanya ND, Essien U, Julien H, Nathan AS, Khatana SAM, Dayoub EJ, Fanaroff AC, Giri J, Groeneveld PW, Adusumalli S.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8050743

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US By Lauren A. Eberly, Lin Yang, Nwamaka D. Eneanya, Utibe Essien, Howard Julien, Ashwin S. Nathan, Sameed Ahmed M. Khatana, Elias J. Dayoub, Alexander C. Fanaroff, Jay Giri, Peter W. Groeneveld, Srinath Adusumalli Published in: JAMA Network Open DOI: 10.1001/jamanetworkopen.2021.6139 ABSTRACT This cohort study evaluates whether inequities in race/ethnicity, gender, and socioeconomic status exist in sodium-glucose cotransporter 2 (SGLT2) inhibitor use among US patients with type 2 diabetes. INTRODUCTION Diabetes is significantly associated with development of cardiovascular and kidney disease in the US.1,2 Sodium-glucose cotransporter 2 (SGLT2) inhibitors decrease kidney glucose reabsorption and thereby increase urinary glucose excretion and improve in blood glucose levels.3 In addition to improved glycemic control, since publication of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus (EMPA-REG) in 2015,4 studies have demonstrated substantial classwide cardioprotective and kidney-protective effect of this medication.5 Among patients with type 2 diabetes at high risk for cardiovascular events, SGLT2 inhibitor use has been shown to significantly reduce death from cardiovascular causes and to lower the risk of hospitalization for heart failure and progression of kidney disease.4,6 Rates of worsening heart failure or cardiovascular death are lower among patients with heart failure who are treated with dapagliflozin and empagliflozin regardless of diabetes diagnosis.7,8 Treatment with dapagliflozin reduces adverse kidney events and decreases mortality among patients with chronic kidney disease (CKD).9 Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control. Black patients have a disproportionately higher burden of cardiovascular and advanced kidney disease.12,13,14,15,16,17,18,19,20 Cardiovascular mortality rates remain highest among Black patients in the US, and racial disparities in the prevalence of major risk factors for coronary heart disease, such as type 2 diabetes, are widening.21,22 Inequitable care delivery based on race is pervasive.23 In addition, inequities in care based on gender and socioeconomic status have been observed.24 Historically, there has been decreased adoption of novel therapies among Black patients as well as among female patients and those with low socioeconomic status.25,26,27 The objective of this study was to evaluate trends in SGLT2 inhibitor prescription by race/ethnicity, gender, and socioeconomic status between 2015 (the year of publication of EMPA-REG) and 2019. We also assessed the association of race/ethnicity, gender, and socioeconomic status with SGLT2 inhibitor use among commercially insured patients with type 2 diabetes in the US, including those with heart failure with reduced ejection fraction (HFrEF), CKD, and atherosclerotic cardiovascular disease (ASCVD); individuals with these comorbidities were evaluated because of the demonstrated benefit of SGLT2 inhibitor use in these particular subgroups. METHODS Study Data This cohort study used data from the Optum Clinformatics Data Mart database, a large administrative private payer claims database of recipients of commercial health insurance and Medicare Advantage health plans, from October 1, 2015, to June 30, 2019. This database consists of inpatient, outpatient, and pharmacy claims of more than 17 million patients annually from all 50 states. Data are updated every 6 to 12 months and are available from January 2004 through June 2019. The University of Pennsylvania institutional review board determined that this research was exempt from the regulatory requirements of the federal Common Rule because no protected health information was used. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. Patient demographic variables, such as age, gender, and race/ethnicity, were available for each member at enrollment. Socioeconomic data, including median household income, were available through zip code–linked enrollment data from the US Census Bureau. Mean number of outpatient cardiology visits and endocrinology visits per 12 months after cohort entry until the end of available data (June 30, 2019) were determined based on patient visits with a cardiology or endocrinology provider with Current Procedural Terminology codes 99201-99205 or 99211-99215 noted in the record. All prescription claims for empagliflozin, dapagliflozin, and canagliflozin (or combination medications) were extracted. Study Cohort We identified adult patients (age, ≥18 years) with a diagnosis of type 2 diabetes based on International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes E11.0, E11.1, or E11.9 between October 2015 and December 2018 to allow for 6 months of continuous enrollment and prescription of therapy after diagnosis given that data were available through June 2019. Each patient was required to have a diagnosis of type 2 diabetes coded on at least 2 occasions on separate dates either as an inpatient or outpatient. Patients entered the cohort on the date of second diagnostic code for type 2 diabetes and were then evaluated for a prescription claim filled for empagliflozin, dapagliflozin, canagliflozin, or any combination medication containing 1 of these SGLT2 inhibitor agents through June 2019. Therefore, the study period for each patient was from the second coded diagnosis of type 2 diabetes to June 2019 (end of available data). Comorbidities were evaluated from the earliest date of available data to the date of cohort entry. Patients were excluded if they had CKD stage IV or V or end-stage kidney disease (ICD-10-CM codes N184, N185, N186, or N189; International Classification of Diseases, Ninth Revision codes: 5854, 5855, 5856, or 5859) any time before cohort entry because SGLT2 inhibitors are contraindicated in this patient population. Patients were also excluded if they did not have continuous insurance enrollment for at least 1 year before and at least 6 months after study entry, so that comorbidities, clinical data, and prescription claims could be accurately obtained for all patients. In addition, patients without any pharmacy claims for medication for 1 year before the study period were excluded to ensure that patients’ medication use was being accurately captured in our data. Subgroup Analysis We performed a subgroup analysis of patients with a diagnosis of HFrEF (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] codes I50.2, I50.21, I50.22, I50.23, I50.4, I50.41, I40.42, and I50.43), those with CKD (stages I, II, and III: ICD-10 codes I12.0, I13.1, N18.x, NI9.x, N25.0, Z49.0, Z49.2, Z94.0, and Z99.2), and those with ASCVD based on ICD-10 codes (eTable 1 in the Supplement). Because rates of lifestyle modification as the sole therapy for type 2 diabetes or adherence to medication therapy may differ between patient groups, we also performed subgroup analysis of patients receiving metformin therapy (prescription claim filled for metformin within 12 months after cohort entry). Statistical Analysis We compared patients who received and did not receive SGLT2 inhibitor treatment over the course of the study period. For each group, summary statistics for patient characteristics are presented as medians with interquartile ranges (IQRs) or means with SDs for continuous data and as total numbers and percentages for categorical data. Continuous variables were compared using the Student t test, and categorical variables were compared using the χ2 test. To assess the association of race/ethnicity with the use of an SGLT2 inhibitor, we estimated multivariable logistic regression models with use of an SGLT2 inhibitor as the dependent variable and independent variables that included age, gender, race/ethnicity (Black,

Read the complete text